Literature DB >> 29120923

Carcinoid-syndrome: recent advances, current status and controversies.

Tetsuhide Ito1, Lingaku Lee2,3, Robert T Jensen3.   

Abstract

PURPOSE OF REVIEW: To review recent advances and controversies in all aspects of carcinoid-syndrome. RECENT
FINDINGS: Over the last few years there have been a number of advances in all aspects of carcinoid syndrome as well as new therapies. These include new studies on its epidemiology which demonstrate it is increasing in frequency; increasing insights into the pathogenesis of its various clinical manifestations and into its natural history: definition of prognostic factors; new methods to verify its presence; the development of new drugs to treat its various manifestations, both initially and in somatostatin-refractory cases; and an increased understanding of the pathogenesis, natural history and management of carcinoid heart disease. These advances have generated several controversies and these are also reviewed.
SUMMARY: There have been numerous advances in all aspects of the carcinoid-syndrome, which is the most common functional syndrome neuroendocrine tumors produce. These advances are leading to new approaches to the management of these patients and in some cases to new controversies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29120923      PMCID: PMC5747542          DOI: 10.1097/MED.0000000000000376

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  200 in total

1.  Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome.

Authors:  A THORSON; G BIORCK; G BJORKMAN; J WALDENSTROM
Journal:  Am Heart J       Date:  1954-06       Impact factor: 4.749

2.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

Review 3.  Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.

Authors:  Javier Molina-Cerrillo; Teresa Alonso-Gordoa; Olga Martínez-Sáez; Enrique Grande
Journal:  Oncologist       Date:  2016-04-22

4.  Coronary artery spasm secondary to carcinoid syndrome.

Authors:  S J Fenning; D E Newby; C Toumpanakis; M W J Strachan
Journal:  QJM       Date:  2016-03-25

5.  Prognosis of carcinoid heart disease: analysis of 200 cases over two decades.

Authors:  Jacob E Møller; Patricia A Pellikka; Alain M Bernheim; Hartzell V Schaff; Joseph Rubin; Heidi M Connolly
Journal:  Circulation       Date:  2005-11-14       Impact factor: 29.690

Review 6.  Pathologic Classification of Neuroendocrine Neoplasms.

Authors:  David S Klimstra
Journal:  Hematol Oncol Clin North Am       Date:  2015-10-24       Impact factor: 3.722

7.  Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation.

Authors:  Sascha Russo; Jim C Boon; Ido P Kema; Pax H B Willemse; Johan A den Boer; Jakob Korf; Elisabeth G E de Vries
Journal:  Psychosom Med       Date:  2004 May-Jun       Impact factor: 4.312

8.  Role of hepatic resection for patients with carcinoid heart disease.

Authors:  Alain M Bernheim; Heidi M Connolly; Joseph Rubin; Jacob E Møller; Christopher G Scott; David M Nagorney; Patricia A Pellikka
Journal:  Mayo Clin Proc       Date:  2008-02       Impact factor: 7.616

9.  Terminal ileal carcinoid tumor without hepatic or extrahepatic metastasis causing carcinoid syndrome.

Authors:  Jashodeep Datta; Nipun B Merchant
Journal:  Am Surg       Date:  2013-04       Impact factor: 0.688

10.  Endobronchial Carcinoid and Concurrent Carcinoid Syndrome in an Adolescent Female.

Authors:  Jonathan D Cogen; Jonathan Swanson; Thida Ong
Journal:  Case Rep Pediatr       Date:  2016-11-08
View more
  26 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

Review 2.  Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis.

Authors:  Jessica E Maxwell; Boris Naraev; Daniel M Halperin; Michael A Choti; Thorvardur R Halfdanarson
Journal:  Ann Surg Oncol       Date:  2022-02-14       Impact factor: 5.344

3.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

Review 4.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

Review 5.  Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.

Authors:  Giuseppe Fanciulli; Rosaria M Ruggeri; Erika Grossrubatscher; Fabio Lo Calzo; Troy D Wood; Antongiulio Faggiano; Andrea Isidori; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

6.  Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy.

Authors:  Paula Soeiro; Helder Martins; Rodolfo Silva; Ana Paula Moreira
Journal:  BMJ Case Rep       Date:  2020-03-31

7.  Rare Presentation of a Metastatic Pancreatic Neuroendocrine Neoplasm Presenting with Atrial Flutter.

Authors:  Paraskevi C Fragkou; Ioannis A Papadopoulos; Antonios Papadopoulos; Evangelos-Achilleas Kontoveros; Gregory Kaltsas; Foula Vassilara
Journal:  Eur J Case Rep Intern Med       Date:  2021-01-20

8.  Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2020-11-11       Impact factor: 3.889

Review 9.  Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.

Authors:  Francesca Spada; Roberta E Rossi; Elda Kara; Alice Laffi; Sara Massironi; Manila Rubino; Franco Grimaldi; Sherrie Bhoori; Nicola Fazio
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-04

Review 10.  Hepatocrinology.

Authors:  Sanjay Kalra; Saptarshi Bhattacharya; Pawan Rawal
Journal:  Med Sci (Basel)       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.